Screening for new peptide substrates for the development of albumin binding anticancer pro-drugs that are cleaved by prostate-specific antigen (PSA) to improve the anti tumor efficacy

Bakheet E.M. Elsadek a, *, Mohammed H. Hassan b

a Department of Biochemistry, Faculty of Pharmacy, Al-Azhar University, Assiut Branch, 71524, Assiut, Egypt
b Department of Medical Biochemistry, Faculty of Medicine, South Valley University, Qena, 83523, Egypt

A R T I C L E  I N F O

Keywords:
Peptide substrate
Prodrug
Spot assay
Prostate-specific antigen (PSA)
Prostate cancer

A B S T R A C T

Several attempts have been made over the past decade to explore the concept of prodrug strategies that exploit PSA as a molecular target for the release of anticancer drugs in prostate tumors using various prostate specific antigen (PSA)-cleavable peptide linkers, but the desired antitumor and antimetastatic efficacy has not yet been fully achieved. We set out to look for new PSA-cleavable peptide substrates that could be cleaved more rapidly and efficiently than the previously used peptides. To look for the most susceptible PSA-cleavable peptide substrates, we used the so-called spot technology. With the following general formula, we designed 25 different fluorogenic heptapeptides; Cellulose-P5-P4-P3-P2-P1-P1′-P2′ (Fluorophore). The increase of the fluorescence in the supernatant of the reaction mixture was monitored using a 96-well fluorometric plate reader with excitation of \( \lambda_{\text{ex}} \) 485 nm and \( \lambda_{\text{em}} \) 535 nm. Three sequences showed a high fluorogenic liberation after incubation with PSA, i.e., Arg-Arg-Leu-His-Tyr-Ser-Leu (7), Arg-Arg-Leu-Asn-Tyr-Ser-Leu (8) and Arg-Ser-Ser-Tyr-Arg-Ser-Leu (23). Future incorporation of these optimized substrates in the PSA-cleavable prodrug formulations could further optimize the cleavage pattern and so the release characteristics of these prodrugs to rapidly and efficiently liberate the free cytotoxic agents inside the tumor tissues.

1. Introduction

Prostate-specific antigen (PSA) is a 33 kDa single-chain glycoprotein [1] composed of 237 amino acid residues, four carbohydrate side chains, and multiple disulfide bonds [2–4]. The amino acid sequence of PSA is homologous to proteases of the kallikrein family and may be referred to as human glandular kallikrein-3 (hK-3) [5]. Whereas most of the other kallikreins have trypsin-like proteolytic activity, PSA is considered a chymotrypsin-like protease based on similarities with chymotrypsin in the specificity of the catalytic site and its preference for cleaving after hydrophobic residues in the P1 position [6].

PSA is aptly named; in that it is specifically and exclusively produced by normal and malignant prostate epithelial cells. Its blood levels used as a screening test for prostate cancer and is not produced in any significant amounts by other normal tissue in the human male [7,8]. The increased secretion of PSA by prostate carcinoma cells coupled with the disruption of normal tissue architecture in the prostate or distal sites by prostate cancer cells results in the leakage of increased amounts of PSA into circulation in a positive correlation with the stage of the disease [7,9].

Interestingly, these PSA molecules have been reported to be secreted in an active form only in the extracellular fluid surrounding prostate carcinoma cells. In the circulation, PSA loses its enzymatic activity as a result of binding to abundant serum protease inhibitors \( \alpha_1 \)-anti-chymotrypsin and \( \alpha_2 \)-macroglobulin, which were reported to be at a 105- to 106-fold molar excess in the circulation of patients with prostate carcinoma [9–12].

Many strategies have previously been investigated to inhibit the protease activity of PSA to control the prostate tumor progression and metastasis but as a result of heterogeneity and autocatalysis, no success was achieved [3,13–16]. In our research, we had investigated the concept of prodrug strategies that exploit PSA as a molecular target for releasing anticancer drugs in prostate tumors. Consequently, and as a main goal of the present work, we set out to look for new optimized PSA-cleavable peptide substrates that could be cleaved more rapidly and efficiently.
2. Materials and methods

2.1. Materials

In collaboration with JPT Peptide Technologies GmbH (Berlin, Germany), we designed 25 different fluorogenic heptapeptides with the following general formula; Cellulose-P\textsubscript{5}-P\textsubscript{4}-P\textsubscript{3}-P\textsubscript{2}-P\textsubscript{1}-P\textsubscript{1}′-P\textsubscript{2}′–(Fluorophore) as seen in (Table 1). The rationale of this design considered that the major physiologic substrates for PSA appear to be the gel-forming proteins in freshly ejaculated semen, semenogelin I and semenogelin II which are synthesized and secreted by the seminal vesicles. Active PSA in the seminal fluid cleaves preferentially after tyrosyl and glutaminyl peptide bonds to generate several low-molecular-weight soluble protein fragments [6, 17, 18]. On this basis of the PSA cleavage map for semenogelin I and semenogelin II, so much information became available about the amino acid sequence proximal to the PSA proteolytic sites as described in (Table 1). With this knowledge, we used the so-called spot technology [19–22], to guess or search for the most susceptible PSA-cleavable peptide substrates.

Each heptapeptide is attached from its C-terminus with Alexa-Fluor-488 as a fluorescent label, whereas the N-terminus is attached to Cellulose disc (Each cellulose disc contains approximately 57 nmol peptide) which is accurately fixed to a well in a 96-well plate (Table 2).

Among the designed 25 fluorogenic substrates there were two PSA-uncleavable heptapeptides, i.e., Arg-Ala-Ser-Tyr-DGln-Ser-Leu (1) and Gly-Gly-Gly-Gly-Gly-Ser-Leu (2) that were included in the study as a negative control. All the other remaining 23 heptapeptides are expected to be PSA cleavable substrates including our previously used heptapeptide substrate i.e., Arg-Ser-Ser-Tyr-Tyr-Ser-Leu (3) which was considered that the major physiologic substrates for PSA appear to be PSA-cleavable peptide substrates. Active PSA in the seminal fluid cleaves preferentially after tyrosyl and glutaminyl peptide bonds to generate several low-molecular-weight soluble protein fragments [6, 17, 18]. On this basis of the PSA cleavage map for semenogelin I and semenogelin II, so much information became available about the amino acid sequence proximal to the PSA proteolytic sites as described in (Table 1). With this knowledge, we used the so-called spot technology [19–22], to guess or search for the most susceptible PSA-cleavable peptide substrates.

The peptides were synthesized on the cellulose discs, starting with a C-terminal Pro residue and Leu in P\textsubscript{1}′ position in all prepared 25 heptapeptides (Table 2), depending on some emerging evidences that have been concluded in our previous work as well as by other investigators. Additionally, these amino acids have been observed to occupy these positions in the natural PSA cleavable substrates and were also used in these positions by other investigators to design some PSA-cleavable substrates [19–22].

The peptides were synthesized on the cellulose discs, starting with a linker system at the C-terminus. The peptides ended at the N-terminus with a free Cysteine residue, where the fluorophore (in this case the Alexa-Fluor-488) was coupled as final step. The evidence of purity for the prepared peptides was provided with their characteristic UV-trace showed that the target mass was found at the peak at 2.8 min as shown in the analysis curve [Fig. 1S].

Enzymatically active PSA was purchased from Calbiochem (Bad Soden, Germany). All other chemicals including methanol, Tris HCl buffer ingredients and solvents were of analytical grade and obtained from standard suppliers and were used without further purification. The

| Table 1 | Identified peptide sequences from the natural PSA substrates Semenogelin I and II (SG-I and SG-II), which are split by PSA [44]. |
| P5 | P4 | P3 | P2 | P1 | P1′ | P2′ | P3′ | P4′ | P5′ |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Lys | Gly | Glu | His | Tyr | Ser | Gly | Glu | Lys | Gly | SG-I 25 |
| Phe | Ser | Ile | Glu | Tyr | Thr | Tyr | His | Val | Asp | SG-I 44 |
| Lys | Ser | Glu | Gly | Tyr | Asp | Leu | Asn | Ala | Leu | SG-I 62; SG-II 62 |
| Ile | Ser | Ser | Glu | Tyr | Ser | Ser | Asn | Thr | Glu | SG-I 136 |
| Glu | Leu | Leu | Val | Tyr | Asn | Lys | Asn | Glu | His | SG-I 240 |
| Arg | Arg | Leu | His | Tyr | Gly | Glu | Asn | Gly | Val | SG-I 277, 337 |
| Gln | Ser | Ser | Ile | Tyr | Ser | Gln | Thr | Glu | Glu | SG-I 292 |
| Glu | Arg | Ser | Ile | Tyr | Ser | Gln | Thr | Glu | Glu | SG-I 352 |
| Ser | Glu | Gly | His | Tyr | Phe | Gly | Gln | Lys | Asp | SG-II 25 |
| Arg | Arg | Leu | Asn | Tyr | Val | Gly | Gly | Lys | Ser | Thr | SG-II 457 |
| Lys | Gly | His | Tyr | Gln | Asn | Val | Val | Glu | Val | SG-I 198; SG-II 198 |
| Ser | Ser | Lys | Val | Gln | Thr | Ser | Leu | Cys | Pro | SG-I 212 |
| Lys | Ile | Ser | Tyr | Gln | Ser | Ser | Ser | Thr | Gla | SG-I 266, 326; SG-II 326, 386 |
| Arg | Ser | Ser | Lys | Leu | Gln | Thr | Ser | Leu | His | Pro | SG-I 212 |
| Lys | Ser | Glu | Asn | Gln | Val | Thr | Ile | His | Ser | SG-II 306 |
| Arg | Ile | Pro | Ser | Gln | Ala | Gln | Gln | Tyr | Gly | SG-II 372 |
| Lys | Met | Ser | Tyr | Gln | Ser | Ser | Ser | Thr | Gla | SG-II 446 |
| Phe | Ser | Ile | Glu | His | Thr | Tyr | His | Val | Asp | SG-II 44 |
| Lys | Lys | Ser | Gln | His | Leu | Gly | Gly | Ser | Gln | SG-II 76 |
| Leu | His | Pro | Ala | His | His | Gly | Gly | Glu | Asp | SG-II 219 |
| Glu | Arg | Glu | Leu | His | His | Gly | Glu | Lys | Ser | SG-II 276 |
| Gly | Glu | Ser | Thr | Asn | Arg | Glu | Gln | Asp | Leu | SG-I 389 |
| Glu | Arg | Arg | Leu | Asn | Ser | Gly | Glu | Lys | Asp | SG-II 396 |
| Gly | Val | Glu | Lys | Asp | Val | Ser | Gln | Ser | Ser | SG-I 285, 345 |
| Ser | Glu | Glu | Leu | Leu | His | Asn | Lys | Glu | Glu | SG-I 84 |
| Ile | Thr | Ile | Pro | Ser | Gln | Glu | Glu | His | SG-I 311 |

Table 2 | The fluorogenic heptapeptides that were designed and examined as PSA substrates. |
| Nr | Cellulose–P\textsubscript{5}-P\textsubscript{4}-P\textsubscript{3}-P\textsubscript{2}-P\textsubscript{1}-P\textsubscript{1}′-P\textsubscript{2}′–Alexa-Fluor-488 |
| --- | --- |
| 1 | Arg-Ala-Ser-Tyr-DGln-Ser-Leu |
| 2 | Gly-Gly-Gly-Gly-Ser-Leu |
| 3 | Arg-Ser-Ser-Tyr-Tyr-Ser-Leu |
| 4 | Lys-Gly-Gln-His-Tyr-Ser-Leu |
| 5 | Ile-Ser-Ser-Gln-Tyr-Ser-Leu |
| 6 | Gln-Ser-Ser-Ile-Tyr-Ser-Leu |
| 7 | Arg-Arg-Leu-His-Tyr-Ser-Leu |
| 8 | Arg-Ala-Leu-Asn-Tyr-Ser-Leu |
| 9 | Arg-Ser-Ser-Ser-Tyr-Ser-Leu |
| 10 | Arg-Ser-Ser-Tyr-Gln-Ser-Leu |
| 11 | Lys-Ile-Ser-Tyr-Gln-Ser-Leu |
| 12 | Lys-Met-Ser-Tyr-Gln-Ser-Leu |
| 13 | Ser-Ser-Lys-Tyr-Gln-Ser-Leu |
| 14 | Ser-Ser-Lys-Val-Gln-Ser-Leu |
| 15 | Lys-Ser-Gln-Asn-Gln-Ser-Leu |
| 16 | Arg-Ile-Pro-Ser-Gln-Ser-Leu |
| 17 | Arg-Ile-Arg-Ser-Gln-Ser-Leu |
| 18 | Arg-Ser-Ser-Tyr-His-Ser-Leu |
| 19 | Lys-Ser-Lys-Gln-Ser-Ser-Leu |
| 20 | Arg-Ser-Ser-Gln-His-Ser-Leu |
| 21 | Arg-Ser-Ser-Ala-His-Ser-Leu |
| 22 | Arg-Ser-Ser-Leu-His-Ser-Leu |
| 23 | Arg-Ser-Ser-Tyr-Arg-Ser-Leu |
| 24 | Ser-Ser-Ser-Arg-Arg-Ser-Leu |
| 25 | Gly-Gln-Ser-Thr-Asn-Ser-Leu |
buffers used were vacuum-filtered through a 0.2 μm membrane (Sartorius, Germany) and thoroughly degassed with ultrasound prior to use. A 96-well fluorometric plate reader with excitation of $\lambda_{\text{ex}}$ 485 nm and $\lambda_{\text{em}}$ 535 nm was used to measure the fluorescence.

2.2. Enzymatic fluorogenic assay

The principle of assay depends on monitoring the increase of the fluorescence in the supernatant of the reaction mixture as a result of the fluorophore liberation after the cleavage of the fluorogenic heptapeptide substrates with PSA (Fig. 1).

Accordingly, each spot was rinsed with methanol for 5 min to solubilize the peptides. Subsequently, it was washed 4 times with 250 μL of 50 mM Tris buffer pH 7.5 with gentle agitation in each step. Afterwards, 250 μL of enzymatically active PSA solution (20 μg/ml) was added to each well. A 50 μL aliquot was transferred directly from each well to its corresponding well in a new 96-well plate containing 50 μL of 50 mM Tris buffer pH 7.5. After mixing, the fluorescence of the new plate was measured to be considered as a 0-time fluorescence level (blank) using a 96-well fluorometric plate reader with excitation of $\lambda_{\text{ex}}$ 485 nm and $\lambda_{\text{em}}$ 535 nm. The reaction mixture was then sealed with a plastic seal and the reaction was allowed to proceed at room temperature without agitation. At 1-h intervals, an aliquot of 50 μL from the reaction supernatant was transferred to a new 96-well plate, diluted and mixed with 50 μL of 50 mM Tris buffer pH 7.5 [23], and its fluorescence was measured as described above. Analysis is performed at JPT using HPLC-MS at 220 nm, linear gradient, 5–95% acetonitrile in water +0.05% TFA.

2.3. Statistical analysis

The results were determined from the initial linear increase of fluorescence till 5 h and were expressed as the mean fluorescence change per hour (ΔF/h) after its analyses by GraphPad Prism version 5.

3. Results

The obtained cleavage results revealed that among the examined 25 fluorogenic heptapeptide substrates, there were three sequences that showed the highest fluorogenic liberation after incubation with PSA (Fig. 2).

These heptapeptides are Arg-Arg-Leu-His-Tyr-Ser-Leu (7), Arg-Arg-Leu-Asn-Tyr-Ser-Leu (8) and Arg-Ser-Ser-Tyr-Arg-Ser-Leu (23). Of note that, this pronounced increase in the rate of fluorescence release in these three heptapeptides was, however, higher than that of our previously used substrate, i.e., Arg-Ser-Ser-Tyr-Tyr-Ser-Leu (3). Additionally, and in a clear conformation for the PSA cleavage liability, the two heptapeptides which were included as negative controls, i.e., Arg-Ala-Ser-Tyr-DGln-Ser-Leu (1) and Gly-Gly-Gly-Gly-Gly-Ser-Leu (2), did not show any significant increase in the florescence rate over the taken period. This can indicate that the three heptapeptides with the highest increase in the fluorescence rate could resemble the best substrates for PSA among the all examined heptapeptides.

4. Discussion

Based on unique biology of PSA (a serine protease), several studies have investigated prodrug strategies that exploit PSA as a molecular target for releasing anticancer drugs from enzymatically cleavable prodrug formulations inside the prostate tumors [12,24–27]. PSA proteolysis of extracellular matrix proteins such as fibronectin and laminin can stimulate the detachment of tumour cells and promote tumour invasion and metastasis, ultimately contributing to the spread and progression of prostate cancer [28,29]. The inhibition and/or consumption of PSA at the tumour site can therefore be a useful method for curing prostate
PSA as a molecular target for releasing anticancer drugs is based mainly on the conjugation of the conventional anticancer drugs with a wide spectrum of low- and high-molecular-weight carriers including sugars, growth factors, vitamins, peptides, antibodies, polysaccharides, lectins, serum proteins, and synthetic polymers through a linker molecule that incorporates a pre-determined breaking point to ensure a tumor-specific release of the drug payload [24, 25].

Denmeade research group introduced a relevant example of the low-molecular weight prodrug strategies that exploit PSA as a molecular target for the release of anticancer drugs from prodrug formulations when they produced an inactive doxorubicin produg that was synthesized by coupling the doxorubicin primary amine to the COOH-terminal carboxyl of a seven-aminocar- peptide carrier (i.e., Mu-His-Ser-Ser-Lys-Leu-Gln-Leu [1], and our previously used heptapeptide substrate, i.e., Arg-Ser-Ser-Thr-Tyr-Tyr-Ser-Leu [33, 34, 35]). Despite the incorporation of these optimized substrates into prodrug formulations could further optimize the pattern of PSA cleavage and thus the release properties of these prodrugs to release the free cytotoxic agents within the tumour tissues quickly and efficiently and thus maximally improve their antitumor and antitemetastatic efficacy.

Our study findings showed that after incubation with PSA, three sequences had high fluorogenic release, i.e., Arg-Arg-Leu-Asn-Tyr-Ser-Leu (7), Arg-Arg-Leu-Asn-Tyr-Ser-Leu (8) and Arg-Ser-Ser-Tyr-Arg-Ser-Leu (23).

In conclusion, there were at least three sequences of the various fluorogenic heptapeptide substrates tested in the current study that showed the highest fluorogenic release after PSA incubation, i.e., Arg-Arg-Leu-Asn-Tyr-Ser-Leu (7), Arg-Arg-Leu-Asn-Tyr-Ser-Leu (8) and Arg-Ser-Ser-Tyr-Arg-Ser-Leu (23). These three sequences may be considered, according to these findings, to be promising candidates for the future production of the corresponding PSA-cleavable prodrugs integrating these substrates.

Informed consent

This manuscript does not contain any studies with human subjects or animals performed by any of the authors.
Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Funding

This study had no funding from any resource.

Authors’ contributions

Study concept and design: BEME and MHH; Data analysis and writing manuscript: BEME and MHH; All authors revised and approved the final version of the manuscript.

Statements

In this work we used the so-called Allexa-spot technology to look for new peptide substrates for the development of albumin binding anti-cancer pro-drugs that are cleaved by prostate-specific antigen (PSA) to improve the anti tumor efficacy.

Declaration of competing interest

The authors declare that they have no known competing financial-interest or personal relationships that could have appeared to influence the final version of the manuscript.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Funding

This study had no funding from any resource.

Authors’ contributions

Study concept and design: BEME and MHH; Data analysis and writing manuscript: BEME and MHH; All authors revised and approved the final version of the manuscript.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.bbrep.2021.100966.

References

[1] S.R. Demnede, A. Nagy, J. Gao, H. Lilija, A.V. Schally, J.T. Isaacs, Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen, Canc. Res. 58 (1998) 2357–2350.
[2] M. Robert, B.F. Gibbs, E. Jacobson, C. Gagnon, Characterization of prostate-specific antigen proteolytic activity on its major physiological substrate, the sperm motility inhibitor precursor/semenogelin I, Biochemistry 36 (1997) 3811–3819.
[3] M.I. Hassan, V. Kumar, T.P. Singh, S. Yadav, Structural model of human PSA: a target for prostate cancer therapy, Chem. Biol. Drug Des. 70 (2007) 261–267.
[4] C.F. Yang, E.S. Porter, J. Boths, D. Kanyi, M. Hsieh, B.S. Cooperman, Design of an albumin-binding prodrug of doxorubicin for targeted therapy for prostate cancer. Mol. Canc. Therapeut., 3(11),1439-1450.
[5] L. Yang, L.Y. Zhang, W.W. Chen, F. Kong, P.J. Zhang, X.Y. Hu, J.Y. Zhang, F.A. Cui, Evaluation of PAP and PSA gene expression in prostatic hyperplasia and prostatic carcinoma using northern-blot analyses, in situ hybridization and immunohistochemical stainings with monoclonal and hispecific antibodies.Int. J. Canc., 55, 590-597.
[6] E.P. Diamandis, New diagnostic applications and physiological functions of prostate specific antigen, Scand. J. Clin. Lab. Invest. Suppl. 221 (1995) 105–112.
[7] E.P. Diamandis, S.I. Helle, H. Yu, D.N. Melegov, S. Lundgren, P.B. Longing, Prognostic value of plasma prostate specific antigen after megestrol acetate treatment in patients with metastatic breast cancer, Cancer 85 (1999) 891–899.
[8] K. Pettersson, L. Viko, P. Henttu, P. Autio-Harmanen, H., Soini, Y.,&Vikho, R., Evaluation of PAP and PSA gene expression in prostatic hyperplasia and prostatic carcinoma using northern-blot analyses, in situ hybridization and immunohistochemical stainings with monoclonal and hispecific antibodies.Int. J. Canc., 55, 590-597.
[9] S.R. Denmeade, L.J. Sokoll, D.W. Chan, S.R. Khan, J.T. Isaacs, Concentration of seminal vesicle protein, J. Clin. Invest. 76 (1985) 1899–1903.
[10] S.R. Denmeade, W. Lou, J. Lovgren, J. Malm, H. Lilja, J.T. Isaacs, Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen, Biochemistry 36 (1997) 3811–3819.
[11] L. Yang, L.Y. Zhang, W.W. Chen, F. Kong, P.J. Zhang, X.Y. Hu, J.Y. Zhang, F.A. Cui, Evaluation of the inhibition of prostate specific antigen by curcumin, Yao Xue Xue Bao 40 (2005) 800-803.
[12] H.J. Petri, M.I. Hassan, M. Loffredo, B. Sussman, A.A. Rendshaw, A.V. D’Amico, Prostate-specific antigen recurrence and mortality after conventional dose radiation therapy in select men with low-risk prostate cancer, Cancer 107 (2006) 2180–2185.
[13] H. Lilija, C.B. Laurell, The predominant protein in human seminal coagulate, Scand. J. Clin. Lab. Invest. 45 (1985) 635–641.
[14] H. Lilija, P.A. Abrahamsson, A. Lundwall, Semenogelin, the predominant protein in human semen. Primary structure and identification of closely related proteins in the male accessory sex glands and on the spermatozoon, J. Biol. Chem. 264 (1989) 1894–1900.
[15] S. Naus, S. Reipschlager, D. Willeber, S.F. Lichtenhaler, S. Mitterreiter, Z. Guan, M.L. Moss, J.W. Bartsch, Identification of candidate substrates for ectodomain shedding by the metalloprotease-disintegrin ADAMBI, Biochem. Biol. Chem. 383 (6) (2002) 1011–1020.
[16] C.H. Jones, P. Dexter, A.K. Evans, C. Ryppa, A. Warnecke, Prodrug strategies in anticancer chemotherapy, ChemMedChem 3 (2008) 20–30.
[17] H. Lilja, C.B. Laurell, The predominant protein in human seminal coagulate, Scand. J. Clin. Lab. Invest. 45 (1985) 635–641.
[18] H. Lilja, C.B. Laurell, The predominant protein in human semen. Primary structure and identification of closely related proteins in the male accessory sex glands and on the spermatozoon, J. Biol. Chem. 264 (1989) 1894–1900.
[19] S. Naus, S. Reipschlager, D. Willeber, S.F. Lichtenhaler, S. Mitterreiter, Z. Guan, M.L. Moss, J.W. Bartsch, Identification of candidate substrates for ectodomain shedding by the metalloprotease-disintegrin ADAMBI, Biochem. Biol. Chem. 383 (6) (2002) 1011–1020.
[20] C.H. Jones, P. Dexter, A.K. Evans, C. Ryppa, A. Warnecke, Prodrug strategies in anticancer chemotherapy, ChemMedChem 3 (2008) 20–30.
[21] H. Lilja, C.B. Laurell, The predominant protein in human seminal coagulate, Scand. J. Clin. Lab. Invest. 45 (1985) 635–641.
[22] K. Keenan, M. Van Zwieten, J.H. Lin, R. Freidinger, J. Huff, A. Oliff, R.E. Jones, Fluorescence polarization assays in small molecule screening, Expet Opin. Drug Discov. 6 (1) (2011) Jan 17–32, https://doi.org/10.1517/17464448.2011.537322.
[23] R. Graeser, D.E. Chung, N. Esser, S. Moor, C. Schachtele, C. Unger, F. Kratz, Synthesis and biological evaluation of an albumin-binding prodrug of doxorubicin that is cleaved by prostate-specific antigen (PSA) in a PSA-positive orthotopic prostate carcinoma model (LNCap), Int. J. Canc. 122 (2008) 1145-1154.
[24] S.R. Denmeade, J.T. Isaacs, Enzymatic activation of prodrugs by prostate-specific antigen: targeted therapy for metastatic prostate cancer, Canc. J. Sci. Am. 4 (1) (2009) S15–S21.
[25] D. DeFreo-Jones, V.M. Garsky, B.K. Wong, D.M. Feng, T. Bolyar, K. Haskell, D. M. Kiefer, K. Leander, E. McAvoy, P. Lamma, J. Wai, E.T. Senderak, S.I. Motzel, K. Keenan, M. Van Zwieten, J.H. Lin, R. Freidinger, J. Huff, A. Oliff, R.E. Jones, A peptide-doxorubicin ‘prodrug’ activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo, Nat. Med. 6 (2000) 1248–1252.
[26] K.L. Greene, P.C. Albertson, R.J. Bashaian, H.B. Carter, P.H. Gann, M. Han, D. A. Kuban, A.O. Sartor, J.L. Stanford, A. Zietman, P. Carroll, Prostate specific antigen best practice statement: 2009 update, J. Urol. 182 (2009) 2232-2241.
[27] A. Caplan, A. Kratz, Prostate-specific antigen and the early diagnosis of prostate cancer, Am. J. Pathol. 117 (2002) S104-S108.
[28] C.W. Cheng, L.W. Chan, C.F. Ng, C.K. Chan, M.K. Tse, M.M. Lai, Breast metastasis from prostate cancer and implication of immunoreactivity to prostate-specific antigen in breast cancer, Int. J. Urol. 13 (2006) 463–465.
[29] M.M. Webber, A. Waghary, D. Bello, Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion, J. Urol. 180 (2008) 2232-2241.
[30] A. Caplan, A. Kratz, Prostate-specific antigen and the early diagnosis of prostate cancer, Am. J. Pathol. 117 (2002) S104-S108.
[31] C.W. Cheng, L.W. Chan, C.F. Ng, C.K. Chan, M.K. Tse, Breast metastasis from prostate cancer and implication of immunoreactivity to prostate-specific antigen in breast cancer, Int. J. Urol. 13 (2006) 463–465.
[32] M.M. Webber, A. Waghary, D. Bello, Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion, J. Urol. 180 (2008) 2232-2241.
cleaved by prostate-specific antigen (PSA), ACS Med. Chem. Lett. 1 (2010) 234–238.

[35] B. Elsadek, R. Graeser, N. Esser, C. Schafer-Obodozie, K.A. Ajaj, C. Unger, A. Warnecke, T. Saleem, N. El-Melegy, H. Madkor, F. Kratz, Development of a novel prodrug of paclitaxel that is cleaved by prostate-specific antigen: an in vitro and in vivo evaluation study, Eur. J. Canc. 46 (2010) 3434–3444.

[36] B. Elsadek, R. Graeser, N. Esser, C. Schafer-Obodozie, C. Tsurumi, K. Abu Ajaj, A. Warnecke, C. Unger, T. Saleem, F. Kratz, In vivo evaluation of a novel albumin-binding prodrug of doxorubicin in an orthotopic mouse model of prostate cancer (LNCaP), Prostate Cancer Prostatic Dis. 14 (2011) 14–21.